Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Operating Expenses (2016 - 2025)

Immucell (ICCC) has disclosed Operating Expenses for 16 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Operating Expenses rose 8.55% year-over-year to $2.3 million, compared with a TTM value of $9.0 million through Sep 2025, up 22.62%, and an annual FY2024 reading of $9.6 million, changed 0.38% over the prior year.
  • Operating Expenses was $2.3 million for Q3 2025 at Immucell, up from $2.2 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $2.7 million in Q3 2022 and bottomed at $1.9 million in Q2 2021.
  • Average Operating Expenses over 5 years is $2.4 million, with a median of $2.3 million recorded in 2023.
  • The sharpest move saw Operating Expenses rose 28.12% in 2022, then dropped 14.09% in 2025.
  • Year by year, Operating Expenses stood at $2.4 million in 2021, then grew by 8.72% to $2.6 million in 2022, then decreased by 6.66% to $2.5 million in 2023, then decreased by 9.82% to $2.2 million in 2024, then grew by 6.01% to $2.3 million in 2025.
  • Business Quant data shows Operating Expenses for ICCC at $2.3 million in Q3 2025, $2.2 million in Q2 2025, and $2.2 million in Q1 2025.